A nurse is caring for a client who is taking montelukast. Which of the following outcomes indicates a therapeutic effect of the medication?
The client's seizure threshold is reduced.
The client experiences less muscle pain.
The client experiences an increased ease of breathing.
The client's platelet count is increased
The Correct Answer is C
Montelukast is a leukotriene receptor antagonist commonly used to manage asthma and allergic rhinitis. Its primary therapeutic effect is to improve respiratory symptoms by reducing inflammation and constriction of the airways. Therefore, an increased ease of breathing would be an expected outcome indicating that the medication is working effectively.
The other options are incorrect because:
A. The client's seizure threshold is reduced: Montelukast does not have any effect on the seizure threshold. This outcome is unrelated to the medication and may be indicative of a different condition or treatment.
B. The client experiences less muscle pain: Montelukast is not indicated for reducing muscle pain. This outcome is unrelated to the medication and may be indicative of a different condition or treatment.
D. The client's platelet count is increased: Montelukast does not have an effect on platelet count. This outcome is unrelated to the medication and may be indicative of a different condition or treatment.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is D
Explanation
Montelukast is typically prescribed as a once-daily medication for the treatment of asthma. Taking it in the evening can be beneficial as it helps to control asthma symptoms throughout the day and night. It is important to follow the prescribed dosing schedule provided by the healthcare provider.
The other statements mentioned are incorrect:
A. "I'll rinse my mouth after taking this medication": Rinsing the mouth after taking montelukast is not necessary as it is not an inhaled medication. Rinsing the mouth is typically recommended after using inhaled corticosteroids to reduce the risk of oral thrush.
B. "I'll take this medication when I get an asthma attack": Montelukast is a long-term control medication used to prevent asthma attacks and manage chronic asthma symptoms. It is not intended for immediate relief during an asthma attack.
C. "I use a spacer device when I inhale this medication": Montelukast is not an inhaled medication, so the use of a spacer device is not applicable. Spacer devices are commonly used with inhaled medications to improve the delivery of the medication to the lungs.
Correct Answer is C
Explanation
Status asthmaticus is a severe and potentially life-threatening asthma exacerbation that does not respond well to usual treatment measures. The primary goal in managing status asthmaticus is to relieve the bronchospasm and improve airflow. Short-acting 62-agonists, such as albuterol, are bronchodilators that work quickly to relax the smooth muscles of the airways, providing immediate relief of bronchospasm.
While determining the cause of the acute exacerbation and obtaining a peak flow reading are important aspects of asthma management, in the case of status asthmaticus, the immediate priority is to administer a bronchodilator to alleviate the severe symptoms and improve the child's breathing. Once the acute symptoms are addressed, further assessment and interventions can be carried out to identify the cause and monitor the child's condition.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today